Prospect research for biotech consultancies
A weekly shortlist with the relevant project work, the reason it may fit your services, contact-research status, and official sources. Inspect a free sample, then start at $249/month.
NIH · NHLBI · SBIR PHASE II
CRI-103 gene therapy as Investigational New Drug for Dilated Cardiomyopathy
The record proposes a GLP pig study, product-specific assays, and an FDA IND. The project began in 2023; manufacturing transfer is already reported complete. An outside advisory need is unconfirmed.
This dated example shows the evidence and its limits. Your sample is researched for your services. See a full example brief →
The useful layer
Every brief is narrow enough to act on and cautious enough to trust. If nothing qualifies, we send nothing—volume never outranks fit.
New NIH and SBIR.gov awards are collected on a bounded schedule, with the original source preserved.
Freshness, phase, value, agency, geography, and product-specific evidence become hard gates, then independent review challenges the fit.
You receive the company, funding event, public-contact research status, why-now cue, caveats, and official link in email and CSV.
AWARDCUE / IND + CMC
Your weekly research shortlistIllustrative layout · verify before outreachNo new dashboard
Built for boutique biotech consultancies
Choose a service and modality. We assess public project evidence against that focus.
Published plans for IND preparation, agency interaction, and early development.
Proposed process, assay, clinical-batch, and manufacturing work to assess for advisory fit.
Study plans and preclinical evidence needs matched to your actual services.
What we will not pretend
01 Service cues are hypotheses. The award terms and company context remain authoritative.
02 Historical contacts are date-labeled; stale, personal, mismatched, and unverified phone details are withheld.
03 AwardCue does not mass-message awardees. Subscribers control and review their own outreach.
Simple monthly plans
Start with the $249 Founding pilot or inspect a free tailored sample. No sales call is required.
Founding pilot
One specialization, one weekly brief, up to 12 qualified signals per month.
Protected
One specialization in an agreed territory, delivered three times weekly.
Secure checkout and billing are provided by Dodo Payments as Merchant of Record. Plans renew monthly. Cancel before the next billing cycle; the 14-day refund policy applies. Qualified volume varies with public award activity, and we never pad a brief.
Straight answers
No. The product is a filtered delivery service. You receive only new signals matched to the service and market you define.
Official public NIH RePORTER and SBIR.gov records. Every lead keeps a link back to the authoritative source.
No. A contact can come from a prior official award record. Its provenance is labeled, and unsafe direct details are withheld, so the present role still must be verified before outreach.
No. That boundary prevents uncontrolled spam and keeps your relationship-building in your hands. We automate the research and delivery.
Dodo Payments is the Merchant of Record for live checkout. Plans renew monthly until canceled. After payment, AwardCue emails a private link to configure your first brief.
We skip the brief when no new records qualify. We can adjust your filters, and monthly plans can be canceled before the next cycle.
Five signals. Your filters. No card.
Tell us your service, modality, and territory. We'll research a current sample with the evidence and limitations included.